Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Subscribe To Our Newsletter & Stay Updated
